RxDoctor Payments DataLook up a doctor →

Ernest Asamoah, MD

Endocrinology, Diabetes & Metabolism · Indianapolis, INNPI 1427079672

Payments from drug & device makers

$959,331in general payments, 2019–2025

Across 2,355 payments — averaging $407.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$362K
  • Lilly USA, LLC$130K
  • AstraZeneca$115K
  • Dexcom, Inc.$80K
  • Amgen$70K
  • Abbott$50K
  • plus $152K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk495$361,601
Lilly USA, LLC285$130,395
AstraZeneca(2 entities)209$115,245
Dexcom, Inc.158$80,307
Amgen(2 entities)197$69,773
Abbott128$49,518
Mannkind Corporation136$41,304
Boehringer Ingelheim76$33,485
Radius Health, Inc.66$17,739
IBSA Pharma Inc.51$15,531
AbbVie46$14,083
Esperion Therapeutics, Inc.8$6,681
Chiesi USA, Inc.9$6,511
Sanofi3$4,558
Vistapharm, Inc.3$2,750
Medtronic(2 entities)57$1,933
Corcept Therapeutics66$1,233
Sanofi-aventis U.S. LLC32$591
Amneal Pharmaceuticals LLC34$534
BETA Bionics, Inc.16$395
Tandem Diabetes Care, Inc.18$392
Novartis18$378
Bayer16$333
Antares Pharma, Inc.24$333
Kyowa Kirin, Inc.7$269
Insulet Corporation13$265
Pfizer13$256
Amarin Pharma, Inc.18$237
Sequel Med Tech, LLC11$225
Merck22$207
Astellas Pharma US Inc8$156
Recordati_rare_diseases_inc.8$147
Companion Medical, Inc.4$144
Xeris Pharmaceuticals, Inc.8$142
Ascendis Pharma Endocrinology Inc7$135
Neurocrine Biosciences, Inc.6$124
Madrigal Pharmaceuticals5$103
Shire North American Group Inc6$101
Ultragenyx Pharmaceutical Inc.5$95
Lifescan, Inc.7$92
Regeneron Healthcare Solutions, Inc.5$90
Eisai Inc.5$81
Arbor Pharmaceuticals, Inc.1$79
Vivus LLC7$77
Cequr Corporation2$70
Kowa Pharmaceuticals America, Inc.5$60
Averitas Pharma Inc.2$56
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$53
Alnylam Pharmaceuticals Inc.2$52
Almatica Pharma LLC3$50
Soleno Therapeutics, Inc.2$48
Senseonics, Incorporated2$36
Amryt Pharma Holdings Ltd2$35
Verity Pharmaceuticals Inc.2$34
Ascensia Diabetes Care US Inc.1$34
Halozyme Inc2$33
GSK2$32
Acella Pharmaceuticals, LLC2$31
Takeda Pharmaceuticals U.S.A., Inc.1$25
EUSA Pharma (US) LLC1$20

How this compares

$959,331 in reported general payments places this provider in the 95th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.

See all endocrinology, diabetes & metabolism providers in Indiana →

Medicare billing

Part B allowed, 2024
$1,006,161
Medicare patients
824
Services billed
34,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Indianapolis

See the full list for Indiana →

Where these figures come from

Is this you, or does something look wrong? →